Pompe Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pompe Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Pompe disease is an inherited disorder caused by defect in a gene called GAA. The GAA gene is responsible for the production of the GAA enzyme (acid alpha-glucosidase). This enzyme is needed to break down glycogen, a form of sugar stored in muscle cells. When too much glycogen builds up in the muscle cells, the cells become damaged and the muscles cannot function properly. Symptoms include respiratory failure, muscle pain, proximal muscle weakness, respiratory tract infections, headache, and difficulty chewing or jaw muscle fatigue.
The Pompe Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Pompe Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pompe Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pompe Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 34 molecules, with 31 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pompe Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pompe Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pompe Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Amicus Therapeutics IncAro Biotherapeutics Co
Asklepios BioPharmaceutical Inc
Astellas Gene Therapies
Astellas Pharma Inc
Avidity Biosciences Inc
AVROBIO Inc
Beijing GeneCradle Technology Co Ltd
BioStrategies LC
CANbridge Life Sciences Ltd
Denali Therapeutics Inc
Eleva GmbH
Entrada Therapeutics Inc
Equaly SA
Erasmus MC
Icagen Inc
ImmunityBio Inc
Intellia Therapeutics Inc
JCR Pharmaceuticals Co Ltd
Lapix Therapeutics Inc
M6P Therapeutics
NanoMedSyn SAS
Oxyrane Belgium NV
Provention Bio Inc
Sanofi
Sarepta Therapeutics Inc
Solid Biosciences Inc
Spark Therapeutics Inc
Takeda Pharmaceutical Co Ltd
University of Florida
University of Massachusetts
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pompe Disease reports